Ruth M Kluck

16PUBLICATIONS
73CO-AUTHORS
Biologically active moleculesCell development, proliferation and deathMolecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Sep 05, 2025
Computational design of potent and selective binders of BAK and BAX.

Stephanie Berger, Erinna F Lee, Tiffany J Harris

|Oct 28, 2024
A lipid signature of BAK-driven apoptotic pore formation.

Rachel T Uren, Matthew E Ritchie, Agnes W Wong

|Apr 06, 2024
A novel inhibitory BAK antibody enables assessment of non-activated BAK in cancer cells.

Hema Preethi Subas Satish, Sweta Iyer, Melissa X Shi

|Feb 09, 2023
Lymphoma cells lacking pro-apoptotic BAX are highly resistant to BH3-mimetics targeting pro-survival MCL-1 but retain sensitivity to conventional DNA-damaging drugs.

Sarah T Diepstraten, Savannah Young, John E La Marca

|Aug 15, 2022
NAb-seq: an accurate, rapid, and cost-effective method for antibody long-read sequencing in hybridoma cell lines and single B cells.

Hema Preethi Subas Satish, Kathleen Zeglinski, Rachel T Uren

|Jun 27, 2022
The BCL-2 family member BID plays a role during embryonic development in addition to its BH3-only protein function by acting in parallel to BAX, BAK and BOK.

Francine S Ke, Steven Holloway, Rachel T Uren

Pageof 3

Frequent Collaborators

8 joint publications

Rachel T Uren

6 joint publications

Sweta Iyer

6 joint publications

Melissa X Shi

3 joint publications

Peter E Czabotar